http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
-
ATARA Biotherapeutics (ATRA) Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188
-
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
-
ATARA Biotherapeutics (ATRA) Announces CHMP Recommends Approval of Ebvallo
-
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
-
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
ATARA Biotherapeutics (ATRA) to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel Commercialization Agreement with Pierre Fabre
-
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
-
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
-
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
-
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
-
Pre-Open Movers: ironSource Surges on Buyback, Tech Stocks Fall on Hot CPI
-
ATARA Biotherapeutics (ATRA) Completes Interim Analysis of ATA188 Phase 2 EMBOLD Study
-
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
-
ATARA Biotherapeutics (ATRA) to Disclose Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, After Market Closes
-
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ATARA Biotherapeutics (ATRA) Reports First Data from Tab-cel European Multicenter Expanded Access Program
-
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting an
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ATARA Biotherapeutics (ATRA) Issues Update on Collaboration with Bayer
-
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
-
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
-
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer
-
Atara Biotherapeutics to Host EBV and MS Day
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
-
UPDATE: ATARA Biotherapeutics (ATRA) Reports Fatal Incident During ATA2271 Autologous CAR T Trial; Halts Further Enrollment
-
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
-
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
-
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple
-
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
-
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
ATARA Biotherapeutics (ATRA) Reports Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel
-
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
-
ATARA Biotherapeutics (ATRA) Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO
